Nivolumab plus Ipilimumab versus Sunitinib in Advanced …
https://pubmed.ncbi.nlm.nih.gov/29562145/
Apr 05, 2018 · Overall survival and objective response rates were significantly higher with nivolumab plus ipilimumab than with sunitinib among intermediate- and poor-risk patients with previously untreated advanced renal-cell carcinoma. (Funded by Bristol-Myers Squibb and Ono Pharmaceutical; CheckMate 214 Clinica …
DA: 68 PA: 58 MOZ Rank: 53